Founded Year
2014Stage
Series A | AliveTotal Raised
$13.14MLast Raised
$2.84M | 3 yrs agoExpert Collections containing Strekin
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Strekin is included in 1 Expert Collection, including Biopharma Tech.
Biopharma Tech
15,535 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Strekin Patents
Strekin has filed 1 patent.
The 3 most popular patent topics include:
- Diseases of the eye and adnexa
- Excipients
- Liberal democracies
Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
4/3/2018 | Diseases of the eye and adnexa, Excipients, Liberal democracies, Life sciences industry, Ophthalmology | Application |
Application Date | 4/3/2018 |
---|---|
Grant Date | |
Title | |
Related Topics | Diseases of the eye and adnexa, Excipients, Liberal democracies, Life sciences industry, Ophthalmology |
Status | Application |
Latest Strekin News
Sep 16, 2019
15 September 2019 | News An international, randomized, placebo-controlled, Phase 3 clinical trial of the investigational drug STR001 in patients following a Sudden Sensorineural Hearing Loss (SSNHL) event Photo credit: dmgpr Strekin AG, a biopharmaceutical company focused on treatments for hearing loss, on 12 Sep 2019, announced that it has successfully completed patient recruitment in the RESTORE study, an international, randomized, placebo-controlled, Phase 3 clinical trial of the investigational drug STR001 in patients following a Sudden Sensorineural Hearing Loss (SSNHL) event. RESTORE is evaluating the ability of STR001 given by intratympanic injection with and without 3-month oral follow-up with STR001 tablets to restore hearing in SSNHL. RESTORE has completed enrollment of the target of 165 patients at approximately 25 clinical centers across 5 European countries. STR001 has been very well tolerated and topline results from RESTORE are anticipated to be released in early 2020. "We are pleased to have completed patient enrollment in the Phase 3 RESTORE clinical trial which is designed to evaluate the ability of STR001 activity to reverse hearing loss following a SSNHL event," remarked Alexander Bausch, Chief Executive Officer of Strekin. "The RESTORE trial tests the ability of STR001 to address a clear unmet medical need in patients who have suffered severe hearing loss that may lead to a debilitating life-long handicap. If successful, the data provided by RESTORE, along with the orphan drug status of STR001 for SSNHL in the EU, may enable STR001 to become the first approved treatment for SSNHL patients."
Strekin Web Traffic
Strekin Rank
When was Strekin founded?
Strekin was founded in 2014.
Where is Strekin's headquarters?
Strekin's headquarters is located at Technologiepark Basel, Basel.
What is Strekin's latest funding round?
Strekin's latest funding round is Series A.
How much did Strekin raise?
Strekin raised a total of $13.14M.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.